Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02062827 · ClinicalTrials.gov registry record · Phase 1
Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
A Phase 1 study of Recurrent Glioblastoma Multiforme and Progressive Glioblastoma Multiforme, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT02062827 is a Phase 1 study of Recurrent Glioblastoma Multiforme and Progressive Glioblastoma Multiforme that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 29 participants, below the 99-participant average among 6 other Recurrent Glioblastoma Multiforme trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02062827, a Phase 1 study of Recurrent Glioblastoma Multiforme and Progressive Glioblastoma Multiforme, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the safety and tolerability of the maximum dose for laboratory engineered Herpes Simplex Virus-1 in patients who would not be eligible for surgical resection of recurrent glioma To determine the safety and tolerability of the maximum dose for laboratory engineered Herpes Simples Virus-1 in patients who would benefit from surgical resection of recurrent glioma
Conditions Studied
Interventions
- BIOLOGICAL M032 (NSC 733972)
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2013-11-25 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02062827
The ClinicalTrials.gov registry entry for NCT02062827 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99-participant average among 6 other Recurrent Glioblastoma Multiforme trials with a reported enrollment target (71% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Recurrent Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which M032 (NSC 733972) is the first listed.
NCT02062827 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT02062827 about?
NCT02062827 is a clinical study titled "Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma". To determine the safety and tolerability of the maximum dose for laboratory engineered Herpes Simplex Virus-1 in patients who would not be eligible for surgical resection of recurrent glioma To determine the safety and tolerability of the maximum dose for laboratory engineered Herpes Simples Virus-1...
What is the current status of trial NCT02062827?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2013-11-25. Estimated completion is 2027-09.
What conditions does trial NCT02062827 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma or Gliosarcoma.
What interventions are being tested in trial NCT02062827?
The interventions under investigation include: M032 (NSC 733972) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02062827?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02062827 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
RECRUITING · Phase 1
-
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
COMPLETED · Phase 1
-
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)
COMPLETED · Phase 2
-
Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
COMPLETED · Phase 2
-
Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)
COMPLETED · Phase 3
Explore more on PlainTrial
Recurrent Glioblastoma Multiforme
All registered trials for this condition
Progressive Glioblastoma Multiforme
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.